Vigil Neuroscience (NASDAQ:VIGL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note released on Thursday,Benzinga reports. They currently have a $17.00 price target on the stock.

Several other equities analysts have also commented on the company. Wedbush upped their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. William Blair started coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $19.75.

Vigil Neuroscience Trading Up 15.8 %

Shares of NASDAQ:VIGL opened at $2.35 on Thursday. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06. The firm’s 50 day moving average price is $2.12 and its 200-day moving average price is $3.12.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. As a group, analysts predict that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

A number of large investors have recently added to or reduced their stakes in VIGL. Ensign Peak Advisors Inc lifted its position in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares in the last quarter. abrdn plc acquired a new position in Vigil Neuroscience in the third quarter worth about $799,000. Point72 Asset Management L.P. bought a new stake in shares of Vigil Neuroscience in the 2nd quarter worth about $5,940,000. Geode Capital Management LLC boosted its holdings in shares of Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after acquiring an additional 66,712 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience in the second quarter valued at $87,000. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.